International normalized ratio (INR) monitoring is essential during oral anticoagulation therapy to minimize bleeding complications and thrombotic events. Laboratory technicians cannot differentiate falsely elevated INR results due to problems in drawing blood from truly elevated INR values, but the extent of this phenomenon is unclear. We determined the proportion of patients with INR values of more than 9 in our laboratory who had values less than 6 in the hospital when retested on the same day. There were 251 tests with an INR of more than 9 (1.84 per 1,000 tests), and 188 of them (74.9%) had an INR of 10 or more, or 1.37 per 1,000 tests sent. There were 20 (33%) of 61 patients with INR values of more than 9 in our laboratory with repeated test values in the hospital of less than 6. Efforts are warranted to decrease this proportion, and patients and physicians should be aware of this phenomenon to prevent dissatisfaction owing to inappropriate expectations.
International normalized ratio (INR) monitoring is essential during oral anticoagulation therapy to minimize bleeding complications and thrombotic events. Laboratory technicians cannot differentiate falsely elevated INR results due to problems in drawing blood from truly elevated INR values, but the extent of this phenomenon is unclear. We determined the proportion of patients with INR values of more than 9 in our laboratory who had values less than 6 in the hospital when retested on the same day. There were 251 tests with an INR of more than 9 (1.84 per 1,000 tests), and 188 of them (74.9%) had an INR of 10 or more, or 1.37 per 1,000 tests sent. There were 20 (33%) of 61 patients with INR values of more than 9 in our laboratory with repeated test values in the hospital of less than 6. Efforts are warranted to decrease this proportion, and patients and physicians should be aware of this phenomenon to prevent dissatisfaction owing to inappropriate expectations.
Accurate international normalized ratio (INR) monitoring is essential during oral anticoagulation therapy to minimize bleeding complications and thrombotic events. 1 Preanalytic problems such as an increased citrate concentration [2] [3] [4] due to underfilling of the blood collection tube is preventable by exclusion of such tubes before analysis, but laboratory technicians cannot differentiate between results with falsely elevated INR results due to problems in drawing blood from truly elevated INR values.
We receive complaints from physicians and their asymptomatic patients, referred to the hospital because of INR values of more than 9, who are then found to have significantly lower results in the hospital despite being retested on the same day. A previous study in an outpatient health maintenance organization coagulation service reported a 6.7% risk of a falsely elevated INR test result of 10 or more that decreased to 4.7% if patients receiving dialysis were excluded, but the study methods might have led to misclassification bias. 3 Patients did not have a repeated INR on the same day, and researchers defined false-positive cases as patients who did not receive treatment with vitamin K and had an INR value of less than 3 the following day. Our health maintenance organization patients with an elevated INR are sent the same day to the hospital for retesting. The purposes of this study were to determine the rate of falsely elevated INR test results in such cases and to identify patient characteristics that might predict false elevations among patients receiving anticoagulation therapy.
Materials and Methods
We obtained data on the age and sex of all active members of the Clalit Health Services, Haifa and Western Galilee, Upon completion of this activity you will be able to: • describe how preanalytical problems might result in a falsely elevated international normalized ratio. • list methods to prevent such problems.
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Haifa, Israel, during December 2008. The results of all prothrombin time tests done during 2008 were recorded, as were the age and sex of the patients. A subsample of tests was compared with tests done in a regional hospital on the same day in patients referred to that hospital. We use 2 Sysmex CA-7000 (Siemens Health Care Diagnostics, Deerfield, IL) coagulation analyzers to determine INR values. Blood samples are received in the central laboratory, centrifuged, and processed within 1 hour. We use thromboplastin of Dade Behring Innovin (Siemens) with an international sensitivity index of 1.05. Collection tubes are 3 mL with 3.2% citrate (Greiner Bio-One, Kremsmünster, Austria). Tests are done only if there is more than 90% filling of the collection tube. Besides accepted internal quality control procedures, we do daily harmonization testing between analyzers and use the National External Quality Assessment Service (NEQAS) external quality control program. Furthermore, for any INR value of 6 or more, the test is repeated immediately 2 times by both analyzers. The last 20 NEQAS tests showed an average value of 2.84 compared with 2.81 for the NEQAS, with a coefficient of variation (CV) of 1.1%. Target values ranged from 1 to 4.75 INR units.
Daily harmonization of 139 tests showed a mean ± SD CV of 0.3% ± 0.6% with a mean INR of 1.41. The mean INR of both analyzers on repeated testing of INR values of 6 or more was identical (6.8 INR) with a mean ± SD CV of 0.6% ± 0.5%. There were no misclassifications (high values from one analyzer not found by the other analyzer).
To determine the degree of interlaboratory variation between our results and for tests done in the hospital, INR samples were tested after centrifugation and then within 6 hours at the hospital; 26 tests were chosen with INR values of less than 6 and 29 tests with INR values of 9 or more. For 26 tests with an INR in our laboratory of less than 6, the mean ± SD values in our laboratory compared with the hospital results were 2.9 ± 1.5 and 2.9 ± 1.2, respectively, with an interlaboratory CV of 3.0%. The mean ± SD value of the 29 tests with an INR of 9 or more was 11.2 ± 3.0 in our laboratory compared with 9.7 ± 4.1 in the hospital (P = .017; Kruskal-Wallis nonparametric analysis of variance) with a CV of 6.2%. There were 16 tests with INR values more than 9 in both laboratories. However, in the other 13 with INR values of 9 or more in our laboratory, the values in the hospital ranged from 6.0 to 8.9. None had values less than 6. Therefore, we considered cases with preanalytic problems to have an INR of more than 9 at our laboratory and less than 6 at the hospital.
For INR samples with results of 6 to 9, all 8 tests had an INR of more than 4 at the hospital. Therefore, we considered a test in the laboratory with a result of 6 to 9 with a subsequent test in the hospital of less than 4 as indicating a preanalytic problem.
The χ 2 test was used to calculate the P values for categorical data. For multivariate analysis, a logistic regression model was used. P values of less than .05 were considered statistically significant.
Ethical Considerations
The data for this study are part of our quality management system. Use of the data is in accordance with the ethical standards established by Clalit Health Services.
Results
The proportion of tests with an INR of 6 to 9 or more than 9 increased with age in females ❚Table 1❚ (odds ratio [OR], 1.37; 95% confidence interval [CI], 1.23-1.51; and OR, 1.56; 95% CI, 1.20-2.23, respectively) per 10 years, and there was a trend for an increased risk in males (Table 1 ; OR, 1.11; 95% CI, 1.0-1.24; and OR, 1.09; 95% CI, 0.87-1.37, respectively) per 10 years. The difference owing to sex was significant, with P values of less than .01 and less than .05 in models predicting an INR of 6 or more and more than 9, respectively. More than half of the high INR values were in people 75 years or older. There were 251 tests with an INR of more than 9 (1.84 per 1,000 tests), and 188 of them (74.9%) had an INR of 10 or more, or 1.37 per 1,000 tests sent. Utilization also increased with age, with more than 1 test per insured member in people 75 years or older, irrespective of sex. 
False-Positive INR Values
For the 61 patients referred to the hospital on the same day as the INR test done in the laboratory with a result of more than 9, 20 (33%) had repeated test values of less than 6 ❚Table 2❚. It is unclear why patients with INR values of 6 to 9 were referred to the emergency department, but 5 (13%) of the 39 patients had INR values less than 4, suggesting a preanalytic problem with the original test.
For 44 patients with values less than 6 and referred for other reasons, 41 (93%) also had values less than 6 in the hospital. There were 2 patients with samples that did not coagulate, suggesting a preanalytic problem in the hospital or an acute condition that caused the increase.
In the 51 patients with INR values of 10 or more and 61 patients with INR values of 9 or more, only 1 patient was receiving dialysis, and he had a retest value in the hospital of 5.1. There were also 4 patients with creatinine values more than 2 mg/dL (177 μmol/L) but not receiving dialysis, and they had concordant values with those found in the hospital.
The only variable that predicted a discordant result was if the patient had a routine test done and had stable values (1.5-3.5) for the last 4 tests done (2-4 weeks apart) ❚Table 3❚. The pretest probability of a false-positive test of 33% increased to 78% (7/9) in patients who had routine testing and stable values.
For the 51 patients with an INR of 10 or more in the laboratory, 5 (10%) had values in the hospital of 3 or less.
Discussion
The major finding of our study is that a preanalytic factor was responsible for nearly a third of INR values of more than 9. This is significantly higher than the 6.7% reported previously. 3 In that study, however, a false-positive result was defined as a repeated INR test value of less than 3 the next day, whereas we were able to show that a repeated INR value of less than 6 on the same day was not compatible with interlaboratory error. Furthermore, our patients did not receive vitamin K before arriving at the hospital. We found that 10% of our patients with an INR of 10 or more had repeated values of 3 or less on retesting, compatible with the results of the previous study. 3 In the previous study, 22 of 53 patients with a falsely elevated INR were receiving dialysis, and such findings were found in 25.6% of tests done on these patients. We had only 1 such case, and, therefore, improper blood sampling in dialysis units does not explain the preanalytic problems with obtaining blood samples in our setting.
There are other factors making it difficult to compare our study with that of the health maintenance organization in the Denver, CO, area. First, no age-sex breakdown was reported in that study. 3 Second, the patient's diagnosis and changes in drug prescriptions available in the Denver area were not available in our study. Still, the number of tests per person per year and the proportion of tests with an INR of 10 or more were nearly identical in the Israeli and Denver cohorts (0.26 compared with 0.21 tests per person per year; 0.14% of tests had an INR of ≥10 in both cohorts). A major difference in the studies was the definition of a falsely elevated INR.
In the previous study, considerable misclassification bias is likely. The researchers considered a false-positive result to be an INR of 10 or more with a next-day result of 3 or less without the administration of vitamin K, yet all patients without a follow-up INR the following day were considered to have a truly elevated INR, as were all patients who received vitamin K or had an INR of more than 3. It was unclear from that study which analyzers were used and if there was harmonization of the first results and of follow-up testing. We were able to use a much more accurate definition, and the results were not confounded by missing values or the use of vitamin K before retesting.
By using the definition of false elevations used by Delate et al, 3 the proportion of false-positives was similar in both studies. However, after removing the data for patients receiving dialysis, the proportion of false-positives was even lower (4.7%), less than half of that found in our study by using their definitions. It is unclear whether this is due to differences in blood sampling techniques, the test tubes, the makeup of the cohort, or analytic method ❚Table 4❚. We have trained nurses from various clinics who draw the blood to follow strict protocols. If the tube is not filled to more than 90% or a clot is present visually, the sample is discarded and reported as insufficiently filled tube or clot. It appeared in the Denver study that 5-mL tubes were nearly exclusively used, whereas in our study, 3-mL tubes were used. In that study, the selected use of pediatric tubes (2.7 mL) resulted in a 6-fold increase in risk for a falsely positive INR compared with a true positive result. 3 However, it has been shown that 90% or more filling in a 2.7-mL pediatric tube is accurate, 4 so that we believe that our results can be extrapolated to other laboratories using 5-mL adult tubes.
The only factor that predicted a falsely elevated INR was routine testing and 4 stable previous INR values; the posttest probability of a false-positive value increased to 78%. This number, however, is imprecise because of small numbers, and it is uncertain if patients in this setting should be managed differently. Others have claimed that if a tube with 2.7 mL is used, then in the absence of bleeding, the result should be confirmed through repeated testing using an adequately filled adult collection tube, with at least 60% of total fill volume for tubes containing 3.2% citrate concentration. 3 The safety of this recommendation is uncertain. An alternative might be to tell the physician and the patient that despite referral for a repeated test, there is a chance that the INR results of the repeated test will be much lower because of preanalytic problems.
It is not clear what the preanalytic factors were that led to falsely elevated INRs. A study of pediatric tubes found that the INR increases as the filling volume decreases. 4 Investigators found, however, that a delay of inversion of the tube of up to 4 minutes and the number of inversions had no effect on the INR value. Because our tests are done only in tubes filled more than 90%, it is unlikely that the proportion of high INR values in our study was affected by filling volume or delayed mixing; it is most likely that the problem arose while obtaining the blood sample. In the Denver study, all patients who had a traumatic puncture during blood sampling or combined blood contents from more than one sample had falsely elevated INR values. 3 A systematic study is needed to assess the time it takes to obtain the blood sample and the degree of trauma that occurs during sampling to more clearly define when an elevated INR can be considered a false-positive result. Staff who obtain blood samples for such testing should be encouraged to not send such samples to the laboratory.
